Delcath Systems Inc. (DCTH) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Delcath Systems Inc. (DCTH)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

12.71

-0.08 (-0.63%)

At close: Jan 14, 2025, 3:59 PM

12.69

-0.16%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	12.45
Market Cap	406.39M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.3
PE Ratio (ttm)	-9.78
Forward PE	n/a
Analyst	Buy

Ask	12.95
Volume	512,112
Avg. Volume (20D)	408,967
Open	12.94
Previous Close	12.79
Day's Range	12.40 - 12.94
52-Week Range	3.70 - 13.30
Beta	undefined

About DCTH

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial fo...

[Show more]

Industry Medical - Specialties

Sector Healthcare

IPO Date May 3, 2018

Employees 76

Stock Exchange NASDAQ

Ticker Symbol DCTH

Website https://www.delcath.com

Analyst Forecast

According to 4 analyst ratings, the average rating for DCTH stock is "Buy." The 12-month stock price forecast is $21.5, which is an increase of 69.16% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Delcath Systems Inc. is scheduled to release its earnings on Mar 25, 2025, before market opens.
Analysts project revenue of $12.42M, reflecting a 2.20K% YoY growth and earnings per share of -0.02, making a -95.83% decrease YoY.

Why Price Moved

2 days ago · Source

+11.41%

Delcath Systems shares are trading higher after th... Unlock content with Pro Subscription

3 months ago · Source

+7.57%

Delcath Systems shares are trading higher after the company announced better-than-expected preliminary Q3 revenue results.

News

1 day ago · zacks.com

Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why

Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

1 week ago · businesswire.com

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

2 weeks ago · businesswire.com

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

1 month ago · businesswire.com

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U...

1 month ago · seekingalpha.com

Delcath Begins Platform Expansion With Two Phase 2 Trials

Delcath's Q3 US sales hit $10 million. This unlocked $25 million in cash from its Tranche B Warrants, which will fund its Phase 2 trials for mCRC and mBC. HEPZATO KIT's hospital rollout is progressing...

1 month ago · seekingalpha.com

Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth

Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 act...

2 months ago · seekingalpha.com

Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript

Delcath Systems Inc (NASDAQ:DCTH ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Ger...

2 months ago · zacks.com

Delcath Systems, Inc. (DCTH) Reports Q3 Loss

Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.61 per share a year ago.

2 months ago · businesswire.com

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

2 months ago · zacks.com

Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 96.84%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 96.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, th...

2 months ago · zacks.com

Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why

Delcath Systems (DCTH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed throug...

2 months ago · businesswire.com

Delcath Systems to Participate in Upcoming Investor Conferences

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...

2 months ago · zacks.com

Delcath Systems, Inc. (DCTH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Delcath Systems (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · businesswire.com

Delcath Systems to Host Third Quarter 2024 Earnings Call

3 months ago · businesswire.com

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results